Ad is loading...
OCS
Price
$14.14
Change
-$0.57 (-3.87%)
Updated
Nov 15 closing price
PRAX
Price
$71.76
Change
-$5.12 (-6.66%)
Updated
Nov 15 closing price
115 days until earnings call
Ad is loading...

OCS vs PRAX

Header iconOCS vs PRAX Comparison
Open Charts OCS vs PRAXBanner chart's image
Oculis Holding AG
Price$14.14
Change-$0.57 (-3.87%)
Volume$42.32K
CapitalizationN/A
Praxis Precision Medicines
Price$71.76
Change-$5.12 (-6.66%)
Volume$552.52K
CapitalizationN/A
OCS vs PRAX Comparison Chart
Loading...
PRAX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
OCS vs. PRAX commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OCS is a Sell and PRAX is a Sell.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (OCS: $14.14 vs. PRAX: $71.76)
Brand notoriety: OCS and PRAX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: OCS: 75% vs. PRAX: 184%
Market capitalization -- OCS: $593.1M vs. PRAX: $1.34B
OCS [@Biotechnology] is valued at $593.1M. PRAX’s [@Biotechnology] market capitalization is $1.34B. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

OCS’s FA Score shows that 0 FA rating(s) are green whilePRAX’s FA Score has 0 green FA rating(s).

  • OCS’s FA Score: 0 green, 5 red.
  • PRAX’s FA Score: 0 green, 5 red.
According to our system of comparison, both OCS and PRAX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PRAX’s TA Score shows that 3 TA indicator(s) are bullish.

  • PRAX’s TA Score: 3 bullish, 5 bearish.

Price Growth

OCS (@Biotechnology) experienced а -13.14% price change this week, while PRAX (@Biotechnology) price change was -7.85% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Reported Earning Dates

OCS is expected to report earnings on Feb 28, 2023.

PRAX is expected to report earnings on Mar 12, 2025.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PRAX($1.34B) has a higher market cap than OCS($593M). PRAX YTD gains are higher at: 222.083 vs. OCS (25.913). OCS has higher annual earnings (EBITDA): -66.46M vs. PRAX (-132.26M). PRAX has more cash in the bank: 352M vs. OCS (118M). OCS has less debt than PRAX: OCS (1.34M) vs PRAX (1.95M). PRAX has higher revenues than OCS: PRAX (1.77M) vs OCS (0).
OCSPRAXOCS / PRAX
Capitalization593M1.34B44%
EBITDA-66.46M-132.26M50%
Gain YTD25.913222.08312%
P/E Ratio63.08N/A-
Revenue01.77M-
Total Cash118M352M34%
Total Debt1.34M1.95M69%
TECHNICAL ANALYSIS
Technical Analysis
PRAX
RSI
ODDS (%)
Bearish Trend 3 days ago
80%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
87%
Momentum
ODDS (%)
Bullish Trend 3 days ago
90%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
89%
Advances
ODDS (%)
Bullish Trend 7 days ago
84%
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
83%
View a ticker or compare two or three
Ad is loading...
PRAX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FREEX19.090.07
+0.37%
Franklin Real Estate Securities A
PRNEX41.42-0.17
-0.41%
T. Rowe Price New Era
USBLX28.05-0.22
-0.78%
Victory Growth and Tax Strategy
MGRRX37.60-0.37
-0.97%
MFS International Growth R1
UAPSX57.32-1.69
-2.86%
ProFunds UltraSmall Cap Svc

OCS and

Correlation & Price change

A.I.dvisor tells us that OCS and PRAX have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that OCS and PRAX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCS
1D Price
Change %
OCS100%
-3.87%
PRAX - OCS
29%
Poorly correlated
-6.66%
GRI - OCS
28%
Poorly correlated
-19.57%
CUE - OCS
28%
Poorly correlated
-17.00%
ENSC - OCS
26%
Poorly correlated
+5.46%
PSTV - OCS
26%
Poorly correlated
-7.14%
More

PRAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRAX has been loosely correlated with VERU. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if PRAX jumps, then VERU could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRAX
1D Price
Change %
PRAX100%
-6.66%
VERU - PRAX
35%
Loosely correlated
-7.20%
INZY - PRAX
35%
Loosely correlated
-8.89%
ZYME - PRAX
34%
Loosely correlated
-5.35%
CLRB - PRAX
33%
Loosely correlated
-7.46%
STRO - PRAX
33%
Loosely correlated
-16.23%
More